CNBC December 8, 2024
Bob Woods

Key Points

– Eli Lilly and Novo Nordisk continue to ramp production facilities and capacity for booming weight-loss drugs like Wegovy and Zepbound, with Lilly this week announcing a $3 billion investment to increase obesity drug production at a Wisconsin plant.

– But supply and demand issues have led to a boom in pharmaceutical cybercrime, with cybersecurity firm McAfee’s Threat Research Team tracking a continued rise throughout 2024 in malicious websites, scam emails and texts, posts on social media and online marketplace listings.

– Consumers are flocking to TikTok and other social media platforms and websites to purchase branded and illicit GLP-1s, often without a prescription.

One interpretation of the law of supply and demand is that when demand outstrips...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
How has U.S. Spending on Health Care Changed Over Time?
Merck enters $2B licensing deal for weight loss drug
How Medicare Negotiated Drug Prices Compare to Other Countries
The Fed's Warnings On Inflation Are Bad News For Biotech Startups
AI Tech Firm SandboxAQ Adds $300M to Ramp Up Development of LQMs for Drug Discovery & More

Share This Article